DRAFT — content pending medical review. Do not share.

Peptide Library / Weight & Metabolic

AOD-9604

Also known as: Anti-Obesity Drug 9604 (GH fragment 176-191)

The fat-loss fragment — the tail end of growth hormone that keeps the fat-burning signal and drops everything else. No appetite suppression, no GLP-1 stomach.

Typical research dose300–500 mcg
Frequency1× daily, fasted morning
RouteSubcutaneous injection
Cycle length8–12 weeks

Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.

What it is

AOD-9604 is amino acids 176–191 of human growth hormone — the specific region responsible for GH's fat-metabolism effects, isolated from the parts that raise IGF-1, affect blood sugar, or grow tissue. It went through actual human obesity trials in the 2000s (it was developed as a pharmaceutical), showed modest fat loss with a clean safety profile, and holds US GRAS status as an ingredient — an unusually documented history for a research compound.

What the research looks at

How protocols are commonly structured

300–500 mcg subcutaneous, fasted, first thing in the morning (fat oxidation is the goal, so it's kept away from food and often paired with fasted cardio), for 8–12 weeks. Honest framing: its effect is a lever, not a truck — the GLP-1 class (semaglutide, tirzepatide) moves more weight; AOD-9604 is chosen when appetite suppression isn't wanted — fighters managing weight while keeping training fuel, or layering onto an already-dialed diet.

Reconstitution & storage

Lyophilized powder; bacteriostatic-water reconstitution (calculator), refrigerate after mixing.

Research protocols, not a prescription — talk to a physician before touching anything.